Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles as a Cell-Free Therapeutic Strategy for Traumatic Brain Injury
4 affiliations
- 1Department of Neurosurgery, Henry Ford Health, Detroit, MI 48202, USA
- 2Department of Physiology, College of Human Medicine, Michigan State University, Lansing, MI 48824, USA
- 3Department of Neurology, Henry Ford Health, Detroit, MI 48202, USA
- 4Department of Physics, Oakland University, Rochester, MI 48309, USA
Abstract
Traumatic brain injury (TBI) is a leading cause of death and long-term neurological disability worldwide. Beyond the initial sudden mechanical insult, TBI is increasingly recognized as a chronic, multisystem disorder involving complex interactions among neurovascular, immune, and metabolic responses. This perspective helps explain the limited success of single-target neuroprotective therapies and underscores the need for multimodal regenerative strategies. Mesenchymal stromal/stem cells (MSCs) have emerged as promising therapeutic candidates for TBI due to their immunomodulatory and reparative properties, which are largely mediated by their secretome, particularly MSC-derived extracellular vesicles (MSC-EVs). These nanoscale vesicles carry selectively packaged nucleic acids, proteins, metabolites, and lipids from their parent cells which mediate intercellular communication and induce repair pathways in recipient cells. Accumulating evidence indicates that MSC-EVs can reduce apoptosis and inflammation, promote angiogenesis, neurogenesis, and synaptic plasticity, and improve functional recovery following TBI. This review examines the current understanding of the multiscale pathophysiology of TBI and the role of brain-derived EVs in mediating crosstalk between the injured brain and peripheral systems in post-TBI multiorgan dysfunction, the translational potential of MSC-EVs in TBI, with a focus on EV cargo engineering, targeted delivery mechanisms, emerging therapeutic strategies, combinatorial regenerative strategies, as well as the growing role of artificial intelligence (AI)-assisted bioengineering in optimizing EV-based therapeutics, and considers future research directions that may facilitate clinical translation.
Related
- Mesenchymal stem cell-derived extracellular vesicles in diabetes: immunomodulation and therapeutic prospects
- Pulsed Focused Ultrasound–Mediated Mechanopriming Enhances the Therapeutic Efficacy of Mesenchymal Stromal Cell–Derived Extracellular Vesicles in Acute Respiratory Distress Syndrome
- Adipose-derived stem cell-derived extracellular vesicles promote critical-sized bone defect repair by enhancing the homing of bone marrow mesenchymal stem cells
- Epithelial-endothelial barrier dysfunction and oxidative stress in ARDS subphenotypes: comparative efficacy of extracellular vesicles derived from bone marrow (MSC-EVs) and adipose tissue (ASC-EVs) mesenchymal stem cells
- ALIX-dependent small extracellular vesicles from tissue-resident mesenchymal cells regulate pancreatic β cell proliferation in obesity
BibTeX
@article{xiong2026mesenchymal,
title = {{Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles as a Cell-Free Therapeutic Strategy for Traumatic Brain Injury}},
author = {Ye Xiong and Yanlu Zhang and Zheng Gang Zhang and Michael Chopp},
journal = {Brain medicine : from neurons to behavior and better health},
year = {2026},
month = jun,
doi = {10.61373/bm026i.0048},
url = {https://doi.org/10.61373/bm026i.0048},
note = {CC BY},
}
RIS
TY - JOUR
TI - Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles as a Cell-Free Therapeutic Strategy for Traumatic Brain Injury
AU - Ye Xiong
AU - Yanlu Zhang
AU - Zheng Gang Zhang
AU - Michael Chopp
PY - 2026
DA - 2026/06/30
JO - Brain medicine : from neurons to behavior and better health
DO - 10.61373/bm026i.0048
UR - https://doi.org/10.61373/bm026i.0048
AB - Traumatic brain injury (TBI) is a leading cause of death and long-term neurological disability worldwide. Beyond the initial sudden mechanical insult, TBI is increasingly recognized as a chronic, multisystem disorder involving complex interactions among neurovascular, immune, and metabolic responses. This perspective helps explain the limited success of single-target neuroprotective therapies and underscores the need for multimodal regenerative strategies. Mesenchymal stromal/stem cells (MSCs) have emerged as promising therapeutic candidates for TBI due to their immunomodulatory and reparative properties, which are largely mediated by their secretome, particularly MSC-derived extracellular vesicles (MSC-EVs). These nanoscale vesicles carry selectively packaged nucleic acids, proteins, metabolites, and lipids from their parent cells which mediate intercellular communication and induce repair pathways in recipient cells. Accumulating evidence indicates that MSC-EVs can reduce apoptosis and inflammation, promote angiogenesis, neurogenesis, and synaptic plasticity, and improve functional recovery following TBI. This review examines the current understanding of the multiscale pathophysiology of TBI and the role of brain-derived EVs in mediating crosstalk between the injured brain and peripheral systems in post-TBI multiorgan dysfunction, the translational potential of MSC-EVs in TBI, with a focus on EV cargo engineering, targeted delivery mechanisms, emerging therapeutic strategies, combinatorial regenerative strategies, as well as the growing role of artificial intelligence (AI)-assisted bioengineering in optimizing EV-based therapeutics, and considers future research directions that may facilitate clinical translation.
SN - 2997-2647
SN - 2997-2639
ER -